n class=”text-remarks” label=”Remarks”>(Danovere) and so on.
Why didn’t you use pharmacoeconomics to measure the price of these drugs and pass the price comparison? Some experts have revealed that the current market price of these drugs is not much different from the price of the interferon program. After these hepatitis C drugs enter the national medical insurance reimbursement system, they can save the whole society by analyzing them according to the perspective of pharmacoeconomics. The future medical expenses of these patients could not find the lowest price, so they chose competitive bidding. It can be seen that the negotiation of hepatitis C drugs will be extremely “tough”.
Most of the varieties are negotiated by means of price comparison, that is, the National Health Insurance Bureau gives the lowest price, and the enterprise quotes twice the price. If both quotations exceed 15% of the lowest price of the Medical Insurance Bureau, it will be out. There is room for negotiation.
For drugs in the rare disease field, the medical insurance bureau is “lighter” when pricing, that is, the price range is not large relative to some oncology drugs. The reason is that these innovative drugs have higher conversion value according to the life value evaluation method in the field of sociology. That is, human life can be converted into money. For example, the total annual GDP of China is the sum of the value created by 1.3 billion people. In this way, if the rare disease drug extends the life of a person for many years, it is how much GDP is increased.
The anti-tumor innovative PD-1 inhibitor, which is expected to be the highest in the future and is popular as a medicinal medicine, has four participating in the negotiations: Merck’s K medicine, Bristol-Myers Squibb O medicine, Junshi bio-Trepril mAb and Cinda’s Centibizumab. They used to have different indications when they were approved for listing in China. They will be included in different groups according to different indications for price negotiation.
After the comprehensive donation assistance, the PD-1 monoclonal antibody that has been listed in China will cost the patient a minimum of 93,600 a year. Some industry insiders and netizens have different voices on the entry of high-priced anticancer drugs into the medical insurance catalogue. Some doctor representatives also disapprove of it and think that they are wasting limited medical insurance resources.